ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.295,98
-0,59%
S&P 500
6.021,63
0,57%
Dow Jones
44.860,31
0,28%
Euro vs US Dollar
1,04868
-0,04%
Bitcoin
92.762,68
0,86%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Amneal Pharmaceuticals Holding Co (AMRX)

  7. Amneal Pharmaceuticals Holding Co (AMRX) News

AMRX

Amneal Pharmaceuticals (AMRX)

Amneal Pharmaceuticals Holding Co
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:AMRX
DatumZeitQuelleÜberschriftSymbolFirma
05/09/202422h05Business WireAmneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administrationNYSE:AMRXAmneal Pharmaceuticals Holding Co
20/08/202417h26Business WireAmneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose VialsNYSE:AMRXAmneal Pharmaceuticals Holding Co
20/08/202414h00Business WireAmneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose VialsNYSE:AMRXAmneal Pharmaceuticals Holding Co
14/08/202421h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
14/08/202417h04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
14/08/202411h56IH Market NewsUBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and MoreNYSE:AMRXAmneal Pharmaceuticals Holding Co
09/08/202412h05Business WireAmneal Reports Second Quarter 2024 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
07/08/202422h45Business WireAmneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release CapsulesNYSE:AMRXAmneal Pharmaceuticals Holding Co
29/07/202422h05Business WireAmneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV BagsNYSE:AMRXAmneal Pharmaceuticals Holding Co
11/07/202422h05Business WireAmneal to Report Second Quarter 2024 Results on August 9, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
09/07/202422h05Business WireAmneal Launches FOCINVEZ™, the First Ready-to-Use Version of FosaprepitantNYSE:AMRXAmneal Pharmaceuticals Holding Co
01/07/202414h00Business WireKashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)NYSE:AMRXAmneal Pharmaceuticals Holding Co
01/07/202414h00Business WireAmneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab BiosimilarNYSE:AMRXAmneal Pharmaceuticals Holding Co
28/06/202414h00Business WireAmneal Releases 2023 Environmental, Social and Governance ReportNYSE:AMRXAmneal Pharmaceuticals Holding Co
05/06/202414h00Business WireAmneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New TherapiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
22/05/202422h05Business WireAmneal to Participate at Upcoming Investor ConferenceNYSE:AMRXAmneal Pharmaceuticals Holding Co
22/05/202422h05Business WireAmneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of CaliforniaNYSE:AMRXAmneal Pharmaceuticals Holding Co
16/05/202421h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
16/05/202421h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
14/05/202422h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
14/05/202422h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
14/05/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
14/05/202422h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
07/05/202422h18Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
06/05/202423h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
06/05/202423h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
06/05/202423h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
06/05/202423h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
06/05/202423h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
03/05/202412h14Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
 Showing the most relevant articles for your search:NYSE:AMRX

Kürzlich von Ihnen besucht

CCOM
SILVER
SILVER
TG
RHM
Rheinmetall
NASDAQ
QQQ
Invesco QQQ Trust Series 1
COIN
ETHUSD
Ethereum
NASDAQ
AMZN
Amazon.com
NYSE
MCD
McDonalds
TG
CBK
Commerzbank
USOTC
BNPQY
BNP Paribas (QX)
FX
EURUSD
Euro vs US Dollar
NYSE
KO
Coca Cola
DBI
TDXP
Tec DAX
NASDAQ
NVDA
NVIDIA
TG
ALV
Allianz
COIN
BTCUSD
Bitcoin
AMEX
XLV
Health Care Select Sector
TG
BAYN
Bayer
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten

BLACK FRIDAY

ADVFN

Seit 25 Jahren im Geschäft 1999-2024

Sparen Sie bis zu 60%* für Euronext Level 2

1 Jahr 40%, 2 Jahre 50% und *3 Jahre 60%

*Über 3 Jahre 1094.04€, jetzt nur noch 437.62€